Additional file 1 of Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium ...
Additional file 1: FigureS1. Sensitivity analysis: treatmentdiscontinuation by product – patients newly initiated on paliperidone palmitateor risperidone microspheres (using a grace period of 120 days). FigureS2. Treatment discontinuation by product and percountry – patients newly initiated on paliperidone palmitate and risperidonemicrospheres. Figure S3. Treatment discontinuation by gender and per country – patientsnewly initiated on paliperidone palmitate and risperidone microspheres. FigureS4. Treatment discontinuation by previoustreatment and per country – patients newly initiated on palip... Mehr ...
| Verfasser: | |
|---|---|
| Dokumenttyp: | Journal contribution |
| Erscheinungsdatum: | 2022 |
| Verlag/Hrsg.: |
figshare
|
| Schlagwörter: | Medicine / Cell Biology / 39999 Chemical Sciences not elsewhere classified / FOS: Chemical sciences / 69999 Biological Sciences not elsewhere classified / FOS: Biological sciences / Developmental Biology / Cancer / Science Policy / 111714 Mental Health / FOS: Health sciences |
| Sprache: | unknown |
| Permalink: | https://search.fid-benelux.de/Record/base-28970166 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | https://dx.doi.org/10.6084/m9.figshare.20023181 |
Additional file 1: FigureS1. Sensitivity analysis: treatmentdiscontinuation by product – patients newly initiated on paliperidone palmitateor risperidone microspheres (using a grace period of 120 days). FigureS2. Treatment discontinuation by product and percountry – patients newly initiated on paliperidone palmitate and risperidonemicrospheres. Figure S3. Treatment discontinuation by gender and per country – patientsnewly initiated on paliperidone palmitate and risperidone microspheres. FigureS4. Treatment discontinuation by previoustreatment and per country – patients newly initiated on paliperidone palmitateand risperidone microspheres. FigureS5. Treatment discontinuation by 30-day averagedose and per country – patients newly initiated on paliperidone palmitate andrisperidone microspheres. FigureS6. Treatment discontinuation by mono- andcombination therapy and per country – patients newly initiated on paliperidonepalmitate and risperidone microspheres. FigureS7. Treatment discontinuation by ...